Pacific Biosciences Q3 Adj EPS $(0.27) Beats $(0.32) Estimate, Sales $55.69M Beat $48.76M Estimate
Portfolio Pulse from mahesh@benzinga.com
Pacific Biosciences (NASDAQ:PACB) reported Q3 losses of $(0.27) per share, beating the analyst consensus estimate of $(0.32) by 15.62%. The company also reported quarterly sales of $55.69 million, surpassing the analyst consensus estimate of $48.76 million by 14.21%. This represents a 72.36% increase over sales from the same period last year.
October 30, 2023 | 8:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacific Biosciences reported better than expected Q3 results, with both EPS and sales beating estimates. This could lead to a positive market reaction.
Pacific Biosciences reported better than expected Q3 results, with both EPS and sales beating estimates. This is generally seen as a positive signal by the market and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100